Health Care • Biotechnology: Pharmaceutical Preparations
$1.48 ▼ +0.00
(-0.34%)
MKT CAP: $658.5M • VOL: 1.77M
52W L $1 52W H $3
ROARABLE / RQD
D- • 39/100
PIOTROSKI
5 / 9
LXRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $49.8M | $6.0M | $1.1M |
| YoY Revenue Growth % | +729.9% | +440.6% | — |
| Gross Profit | $49.5M | $5.4M | — |
| Gross Margin % | 98.0% | 89.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$48.9M | -$197.1M | -$171.8M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$50.3M | -$200.4M | -$177.1M |
| EBITDA (Normalized) | -$48.9M | -$196.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$67.9M | -$178.8M | -$161.9M |
| Capital Expenditures (CapEx) | $0 | $1.0M | — |
| Free Cash Flow (FCF) | -$67.9M | -$179.8M | -$161.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -31.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $34.3M | $66.7M | — |
| Total Debt (Short + Long Term) | $49.4M | $100.3M | — |
| Total Stockholders' Equity | $107.5M | $145.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LXRX.